CMMB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Stats
Today's Volume	53 508.00
Average Volume	251 884
Market Cap	11.96M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.200 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.410
ATR14	$0.0160 (1.94%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-14	Darvish Nissim	Buy	20 572	Option to Purchase American Depositary Shares
2021-04-19	Darvish Nissim	Buy	11 884	Option to Purchase American Depositary Shares
2016-10-28	Darvish Nissim	Buy	10 123	Option to Purchase American Depositary Shares
2023-03-16	Darvish Nissim	Buy	6 857	Option to Purchase American Depositary Shares
2022-03-07	Darvish Nissim	Buy	6 820	Option to Purchase American Depositary Shares

INSIDER POWER
-56.78
Last 88 transactions
Buy: 2 375 207 \| Sell: 4 584 307

Volume Correlation

Long: -0.12 (neutral)

Short: -0.92 (very strong negative)

Signal:(43.204) Neutral

Anchiano Therapeutics Ltd Correlation

10 Most Positive Correlations
NVMI	0.915
SBLK	0.903
TXRH	0.902
CVLT	0.901
KLAC	0.899
PEZ	0.896
ESPO	0.895
GOGL	0.894
WING	0.894
BUFF	0.893

10 Most Negative Correlations
WISA	-0.868
BMRN	-0.863
KLXE	-0.861
BNRG	-0.857
ESCA	-0.855
HFFG	-0.852
SVC	-0.852
NYMT	-0.852
FWRD	-0.852
VREX	-0.852

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Anchiano Therapeutics Ltd Correlation - Currency/Commodity

-0.19
( neutral )

-0.23
( neutral )

0.00
( neutral )

0.45
( neutral )

Anchiano Therapeutics Ltd Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-66 827.00 (0.00 %)
EPS:	$-2.06

FY	2023
Revenue:	$0
Gross Profit:	$-66 827.00 (0.00 %)
EPS:	$-2.06

FY	2022
Revenue:	$0
Gross Profit:	$-57 773.00 (0.00 %)
EPS:	$-2.43

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.200

Financial Reports:

No articles found.

Anchiano Therapeutics Ltd Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Anchiano Therapeutics Ltd

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.